Selective labeling and localization of the M4 (m4) muscarinic receptor subtype

G Ferrari-Dileo, M Waelbroeck, DC Mash and DD Flynn

Department of Molecular and Cellular Pharmacology, University of Miami School of Medicine, Florida 33101.

We report here a novel strategy for the selective labeling and localization of the M4 (m4) muscarinic receptor subtype, based on the distinct kinetics of the muscarinic antagonists dexetimide and N- methylscopolamine (NMS) and on the selectivity profile of guanylpirenzepine and AF-DX 116 for the m1-m5 muscarinic receptor subtypes expressed in CHO-K1 cells. Incubation with 10 nM dexetimide, a nonselective antagonist, resulted in > 90% occupancy of each of the m1- m5 receptor subtypes. The relatively rapid rates of dexetimide dissociation from the m1, m2, and m4 receptor subtypes (t1/2 values of < 12.5 min) and the slower rates of dexetimide dissociation from the m3 and m5 receptor subtypes (t1/2 values of 65 and 75 min, respectively) favored the labeling of the m1, m2, and m4 receptor subtypes with short incubations with [3H]NMS. Inclusion of 200 nM guanylpirenzepine and 250 nM AF-DX 116 prevented the binding of [3H]NMS to the majority of the m1 and m2 receptor subtypes, respectively, resulting in primary labeling of the m4 receptor subtype. Brief dissociation of the radioligand in the presence of 1 microM atropine improved the ratio of m4 to m2 labeling by selectively removing [3H]NMS from the m2 subtype. Under these conditions, the ratio of [3H]NMS binding to the m4 versus m1, m2, m3, and m5 receptor subtypes was 4:1. In vitro autoradiography combined with these m4-selective labeling conditions demonstrated that the M4 (m4) receptor subtype was localized to the primary visual area (V1, area 17, occipital cortex) and the basal ganglia, a distribution distinct from that demonstrated for the M1 (m1), M2 (m2), and M3 (m3) receptor subtypes. These results demonstrate that a combination of the distinct kinetics of dexetimide and NMS and the receptor subtype selectivity of guanylpirenzepine and AF-DX 116 provides a valuable labeling strategy to examine the distribution and localization of the M4 (m4) muscarinic receptor subtype in brain, peripheral tissues, and cell lines.

Volume 46, Issue 6, pp. 1028-1035, 12/01/1994
Copyright © 1994 by American Society for Pharmacology and Experimental Therapeutics

This article has been cited by other articles:

				W. A. Luft, Y. Ming, and W. K. Stell Variable Effects of Previously Untested Muscarinic Receptor Antagonists on Experimental Myopia Invest. Ophthalmol. Vis. Sci., March 1, 2003; 44(3): 1330 - 1338. [Abstract] [Full Text] [PDF]

				M. C. Olianas, A. Ingianni, C. Maullu, A. Adem, E. Karlsson, and P. Onali Selectivity Profile of Muscarinic Toxin 3 in Functional Assays of Cloned and Native Receptors J. Pharmacol. Exp. Ther., January 1, 1999; 288(1): 164 - 170. [Abstract] [Full Text]

				S. L. Purkerson and L. T. Potter Use of Antimuscarinic Toxins To Facilitate Studies of Striatal m4 Muscarinic Receptors J. Pharmacol. Exp. Ther., February 1, 1998; 284(2): 707 - 713. [Abstract] [Full Text]

				A. P. Gadbut, D. Riccardi, L. Wu, S. C. Hebert, and J. B. Galper Specificity of Coupling of Muscarinic Receptor Isoforms to a Novel Chick Inward-rectifying Acetylcholine-sensitive K[IMAGE] Channel J. Biol. Chem., March 15, 1996; 271(11): 6398 - 6402. [Abstract] [Full Text] [PDF]

				G. L. Forster, J. S. Yeomans, J. Takeuchi, and C. D. Blaha M5 Muscarinic Receptors Are Required for Prolonged Accumbal Dopamine Release after Electrical Stimulation of the Pons in Mice J. Neurosci., January 1, 2002; 22(1): RC190 - RC190. [Abstract] [Full Text] [PDF]